Advertisement

November 5, 2019

First Robotic-Assisted Aneurysm Coiling Performed With Corindus' CorPath GRX System

November 5, 2019—Corindus, a Siemens Healthineers company that develops precision vascular robotics, announced that its CorPath GRX system was used to complete the first-in-human robotic-assisted neurovascular intervention.

According to the company, the robotic- and stent-assisted aneurysm coiling case marked a significant milestone, building toward a new interventional treatment paradigm for patients with neurovascular disease. The procedure was performed by the team led by Vitor Mendes Pereira, MD, a neurosurgeon and neuroradiologist at the Toronto Western Hospital and Krembil Brain Institute in Toronto, Ontario, on November 1.

Before the procedure, Dr. Pereira performed a rehearsal procedure on a Biomodex three-dimensional (3D)–printed flow model of the specific anatomy of the patient, a 64-year-old female Canadian resident. Using the 3D model allowed Dr. Pereira to develop a plan for the novel robotic procedure and ensure an optimal treatment approach.

During the actual procedure, neuroradiologists Timo Krings, MD, and Patrick Nicholson, MD, provided bedside physician support. Medical radiation technologist, Nicole Cancelliere, acted as the bedside robotic technician.

Dr. Pereira commented in the company’s announcement, “Precision is a key element of neurovascular interventions, and it is evident to me that augmenting these delicate procedures with robotic assistance can positively impact how we treat patients. I felt honored to perform this procedure and look forward to continuing to support the development of robotic technology to help address access issues of stroke patients in the community.”

In October, Siemens Healthineers AG completed its acquisition of Corindus to accelerate the development of robotic technology to address the existing problem of access to care for emergent procedures for conditions such as heart attack and stroke.

Advertisement


November 5, 2019

Four-Year Data Presented From Medtronic's IN.PACT Global Study

November 5, 2019

Trial Data Presented for Boston Scientific's Ranger DCB and Eluvia DES